Literature DB >> 14600159

Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2).

Yasuo Yamazaki1, Koji Takani, Hideko Atoda, Takashi Morita.   

Abstract

Vascular endothelial growth factor (VEGF165) exhibits multiple effects via the activation of two distinct endothelial receptor tyrosine kinases: Flt-1 (fms-like tyrosine kinase-1) and KDR (kinase insert domain-containing receptor). KDR shows strong ligand-dependent tyrosine phosphorylation in comparison with Flt-1 and mainly mediates the mitogenic, angiogenic, and permeability-enhancing effects of VEGF165. Here we show the isolation of two VEGFs from viper venoms and the characterization of their unique biological properties. Snake venom VEGFs strongly stimulated proliferation of vascular endothelial cells in vitro. Interestingly, the maximum activities were almost twice that of VEGF165. They also induced strong hypotension on rat arterial blood pressure compared with VEGF165 in vivo. A receptor binding assay revealed that snake venom VEGFs bound to KDR-IgG with high affinity (Kd = approximately 0.1 nm) as well as to VEGF165 but did not interact with Flt-1, Flt-4, or neuropilin-1 at all. Our data clearly indicate that snake venom VEGFs act through the specific activation of KDR and show potent effects. Snake venom VEGFs are a highly specific ligand to KDR and form a new group of the VEGF family.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600159     DOI: 10.1074/jbc.C300454200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Gene and protein therapies utilizing VEGF for ALS.

Authors:  Orion P Keifer; Deirdre M O'Connor; Nicholas M Boulis
Journal:  Pharmacol Ther       Date:  2013-10-29       Impact factor: 12.310

2.  The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis.

Authors:  Selcuk Tunik; Yusuf Nergiz; Ugur Keklikci; Murat Akkus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-15       Impact factor: 3.117

Review 3.  Therapeutic potential of snake venom in cancer therapy: current perspectives.

Authors:  Vivek Kumar Vyas; Keyur Brahmbhatt; Hardik Bhatt; Utsav Parmar
Journal:  Asian Pac J Trop Biomed       Date:  2013-02

4.  Snake venom Vascular Endothelial Growth Factors (VEGF-Fs) exclusively vary their structures and functions among species.

Authors:  Yasuo Yamazaki; Yukiko Matsunaga; Yuko Tokunaga; Shinya Obayashi; Mai Saito; Takashi Morita
Journal:  J Biol Chem       Date:  2009-02-10       Impact factor: 5.157

5.  A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors.

Authors:  Steven A Stacker; Michael M Halford; Sally Roufail; Carol Caesar; Marc G Achen
Journal:  J Vis Exp       Date:  2016-03-15       Impact factor: 1.355

6.  Novel vascular endothelial growth factor D variants with increased biological activity.

Authors:  Pyry I Toivanen; Tiina Nieminen; Lenita Viitanen; Annamari Alitalo; Miia Roschier; Suvi Jauhiainen; Johanna E Markkanen; Olli H Laitinen; Tomi T Airenne; Tiina A Salminen; Mark S Johnson; Kari J Airenne; Seppo Ylä-Herttuala
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

Review 7.  Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.

Authors:  Gang Niu; Xiaoyuan Chen
Journal:  Curr Drug Targets       Date:  2010-08       Impact factor: 3.465

Review 8.  Molecular and functional diversity of vascular endothelial growth factors.

Authors:  Yasuo Yamazaki; Takashi Morita
Journal:  Mol Divers       Date:  2006-11       Impact factor: 3.364

Review 9.  Pharmacological aspects of Vipera xantina palestinae venom.

Authors:  Tatjana Momic; Franziska T Arlinghaus; Hadar Arien-Zakay; Jeoshua Katzhendler; Johannes A Eble; Cezary Marcinkiewicz; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2011-11-14       Impact factor: 4.546

Review 10.  Old World Vipers-A Review about Snake Venom Proteomics of Viperinae and Their Variations.

Authors:  Maik Damm; Benjamin-Florian Hempel; Roderich D Süssmuth
Journal:  Toxins (Basel)       Date:  2021-06-17       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.